Provider: Silverchair
Database: AmericanMedicalAssociation
Content: text/plain; charset="UTF-8"

TY  - JOUR
AU  - Martin, Richard M.
AU  - Turner, Emma L.
AU  - Young, Grace J.
AU  - Metcalfe, Chris
AU  - Walsh, Eleanor I.
AU  - Lane, J. Athene
AU  - Sterne, Jonathan A. C.
AU  - Noble, Sian
AU  - Holding, Peter
AU  - Ben-Shlomo, Yoav
AU  - Williams, Naomi J.
AU  - Pashayan, Nora
AU  - Bui, Mai Ngoc
AU  - Albertsen, Peter C.
AU  - Seibert, Tyler M.
AU  - Zietman, Anthony L.
AU  - Oxley, Jon
AU  - Adolfsson, Jan
AU  - Mason, Malcolm D.
AU  - Davey Smith, George
AU  - Neal, David E.
AU  - Hamdy, Freddie C.
AU  - Donovan, Jenny L.
AU  - CAP Trial Group
T1  - Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial
PY  - 2024
Y1  - 2024/05/07
DO  - 10.1001/jama.2024.4011
JO  - JAMA
JA  - JAMA
VL  - 331
IS  - 17
SP  - 1460
EP  - 1470
SN  - 0098-7484
AB  - The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality at a median 10-year follow-up (primary outcome), but the long-term effects of PSA screening on prostate cancer mortality remain unclear.To evaluate the effect of a single invitation for PSA screening on prostate cancer–specific mortality at a median 15-year follow-up compared with no invitation for screening.This secondary analysis of the CAP randomized clinical trial included men aged 50 to 69 years identified at 573 primary care practices in England and Wales. Primary care practices were randomized between September 25, 2001, and August 24, 2007, and men were enrolled between January 8, 2002, and January 20, 2009. Follow-up was completed on March 31, 2021.Men received a single invitation for a PSA screening test with subsequent diagnostic tests if the PSA level was 3.0 ng/mL or higher. The control group received standard practice (no invitation).The primary outcome was reported previously. Of 8 prespecified secondary outcomes, results of 4 were reported previously. The 4 remaining prespecified secondary outcomes at 15-year follow-up were prostate cancer–specific mortality, all-cause mortality, and prostate cancer stage and Gleason grade at diagnosis.Of 415 357 eligible men (mean [SD] age, 59.0 [5.6] years), 98% were included in these analyses. Overall, 12 013 and 12 958 men with a prostate cancer diagnosis were in the intervention and control groups, respectively (15-year cumulative risk, 7.08% [95% CI, 6.95%-7.21%] and 6.94% [95% CI, 6.82%-7.06%], respectively). At a median 15-year follow-up, 1199 men in the intervention group (0.69% [95% CI, 0.65%-0.73%]) and 1451 men in the control group (0.78% [95% CI, 0.73%-0.82%]) died of prostate cancer (rate ratio [RR], 0.92 [95% CI, 0.85-0.99]; P = .03). Compared with the control, the PSA screening intervention increased detection of low-grade (Gleason score [GS] ≤6: 2.2% vs 1.6%; P < .001) and localized (T1/T2: 3.6% vs 3.1%; P < .001) disease but not intermediate (GS of 7), high-grade (GS ≥8), locally advanced (T3), or distally advanced (T4/N1/M1) tumors. There were 45 084 all-cause deaths in the intervention group (23.2% [95% CI, 23.0%-23.4%]) and 50 336 deaths in the control group (23.3% [95% CI, 23.1%-23.5%]) (RR, 0.97 [95% CI, 0.94-1.01]; P = .11). Eight of the prostate cancer deaths in the intervention group (0.7%) and 7 deaths in the control group (0.5%) were related to a diagnostic biopsy or prostate cancer treatment.In this secondary analysis of a randomized clinical trial, a single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years. However, the absolute reduction in deaths was small.isrctn.org Identifier: ISRCTN92187251
Y2  - 6/2/2024
UR  - https://doi.org/10.1001/jama.2024.4011
ER  -